id,document,pd_l1,pd_l1_available,tmb,tmb_available,msi_h,msi_h_available,progressive_disease,progressive_disease_available,prior_therapy_failure,prior_therapy_failure_available,mutations,mutations_available,risk_score,decision
case_0001,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",90,True,18,True,False,False,True,True,False,False,[],False,0.81,Approved
case_0002,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0003,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,25,True,True,True,True,True,False,False,['BRAF+'],True,0.96,Approved
case_0004,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0005,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0006,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,25,True,False,False,True,True,True,True,[],False,0.79,Approved
case_0007,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0008,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.65).",50,True,18,True,False,False,True,True,False,False,[],False,0.65,Borderline
case_0009,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0010,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0011,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.74).",10,True,5,True,True,True,True,True,True,True,['HER2+'],True,0.74,Approved
case_0012,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0013,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0014,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.48).",20,True,8,True,True,True,False,False,False,False,[],False,0.48,Rejected
case_0015,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,18,True,False,False,True,True,True,True,"['EGFR+', 'BRAF+']",True,0.97,Approved
case_0016,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0017,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,12,True,False,False,True,True,True,True,[],False,0.75,Approved
case_0018,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0019,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0020,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,12,True,False,False,True,True,False,False,"['EGFR+', 'ALK+']",True,0.79,Approved
case_0021,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,25,True,False,False,True,True,True,True,"['ALK+', 'HER2+']",True,0.89,Approved
case_0022,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",100,True,18,True,False,False,True,True,False,False,['HER2+'],True,0.9,Approved
case_0023,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0024,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0025,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,12,True,True,True,True,True,True,True,[],False,0.89,Approved
case_0026,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.54).",10,True,8,True,False,False,True,True,False,False,['EGFR+'],True,0.54,Borderline
case_0027,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,18,True,True,True,True,True,False,False,"['BRAF+', 'EGFR+']",True,0.89,Approved
case_0028,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",50,True,18,True,True,True,True,True,True,True,['BRAF+'],True,0.9,Approved
case_0029,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0030,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0031,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",80,True,12,True,True,True,True,True,True,True,"['ALK+', 'HER2+']",True,1.0,Approved
case_0032,The tumor shows 20% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. There has been a failure of prior therapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.48).,20,True,8,True,False,False,False,False,True,True,[],False,0.48,Rejected
case_0033,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.94).",60,True,12,True,True,True,True,True,True,True,['EGFR+'],True,0.94,Approved
case_0034,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,25,True,True,True,True,True,True,True,['BRAF+'],True,1.0,Approved
case_0035,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0036,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,18,True,False,False,True,True,True,True,['EGFR+'],True,0.96,Approved
case_0037,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,12,True,False,False,True,True,True,True,"['BRAF+', 'EGFR+']",True,1.0,Approved
case_0038,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",50,True,12,True,True,True,True,True,True,True,"['EGFR+', 'BRAF+']",True,0.95,Approved
case_0039,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.86).",40,True,5,True,True,True,True,True,True,True,['HER2+'],True,0.86,Approved
case_0040,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,12,True,True,True,True,True,False,False,['EGFR+'],True,0.96,Approved
case_0041,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.63).",20,True,5,True,False,False,True,True,True,True,[],False,0.63,Borderline
case_0042,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.61).",40,True,8,True,False,False,False,False,True,True,['HER2+'],True,0.61,Borderline
case_0043,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,False,False,True,True,False,False,"['HER2+', 'EGFR+']",True,0.95,Approved
case_0044,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0045,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0046,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0047,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.64).",10,True,12,True,True,True,True,True,False,False,['EGFR+'],True,0.64,Borderline
case_0048,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0049,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,True,True,[],False,1.0,Approved
case_0050,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0051,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0052,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0053,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,12,True,False,False,True,True,True,True,[],False,0.79,Approved
case_0054,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.53).",20,True,5,True,False,False,False,False,True,True,['HER2+'],True,0.53,Borderline
case_0055,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0056,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0057,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,25,True,True,True,True,True,False,False,"['BRAF+', 'EGFR+']",True,1.0,Approved
case_0058,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0059,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,25,True,False,False,True,True,True,True,[],False,0.75,Approved
case_0060,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",90,True,12,True,False,False,True,True,False,False,[],False,0.81,Approved
case_0061,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,25,True,False,False,True,True,False,False,"['HER2+', 'BRAF+']",True,0.79,Approved
case_0062,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,18,True,True,True,True,True,False,False,[],False,0.75,Approved
case_0063,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",40,True,8,True,True,True,True,True,True,True,[],False,0.81,Approved
case_0064,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.64).",10,True,8,True,False,False,True,True,True,True,['HER2+'],True,0.64,Borderline
case_0065,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0066,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.84).",60,True,18,True,False,False,True,True,True,True,['HER2+'],True,0.84,Approved
case_0067,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0068,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",50,True,25,True,False,False,True,True,True,True,"['HER2+', 'BRAF+']",True,0.85,Approved
case_0069,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0070,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,8,True,True,True,False,False,True,True,['EGFR+'],True,0.71,Approved
case_0071,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0072,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,12,True,True,True,True,True,False,False,[],False,0.91,Approved
case_0073,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,False,False,True,True,True,True,"['BRAF+', 'EGFR+']",True,1.0,Approved
case_0074,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0075,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0076,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0077,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,25,True,False,False,True,True,False,False,"['HER2+', 'ALK+']",True,0.91,Approved
case_0078,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.86).",90,True,12,True,False,False,True,True,False,False,['ALK+'],True,0.86,Approved
case_0079,The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. There has been a failure of prior therapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.48).,20,True,12,True,False,False,False,False,True,True,[],False,0.48,Rejected
case_0080,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0081,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0082,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0083,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0084,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0085,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",40,True,12,True,True,True,True,True,True,True,[],False,0.81,Approved
case_0086,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.58).",20,True,12,True,False,False,True,True,False,False,['EGFR+'],True,0.58,Borderline
case_0087,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0088,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,False,False,True,True,True,True,"['EGFR+', 'ALK+']",True,1.0,Approved
case_0089,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.44).",10,True,8,True,True,True,False,False,False,False,[],False,0.44,Rejected
case_0090,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,8,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0091,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,12,True,True,True,True,True,True,True,[],False,0.97,Approved
case_0092,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0093,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0094,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,12,True,True,True,True,True,True,True,[],False,0.97,Approved
case_0095,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.53).",20,True,5,True,False,False,False,False,True,True,['HER2+'],True,0.53,Borderline
case_0096,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,12,True,True,True,True,True,True,True,['ALK+'],True,1.0,Approved
case_0097,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.87).",80,True,18,True,False,False,True,True,True,True,[],False,0.87,Approved
case_0098,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0099,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",80,True,18,True,True,True,True,True,True,True,['HER2+'],True,1.0,Approved
case_0100,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,5,True,False,False,True,True,True,True,[],False,0.71,Approved
case_0101,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.84).",60,True,12,True,True,True,True,True,False,False,['BRAF+'],True,0.84,Approved
case_0102,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,False,False,True,True,True,True,['BRAF+'],True,1.0,Approved
case_0103,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,25,True,True,True,True,True,False,False,[],False,0.91,Approved
case_0104,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,5,True,True,True,True,True,False,False,[],False,0.71,Approved
case_0105,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,12,True,True,True,True,True,False,False,[],False,0.71,Approved
case_0106,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0107,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0108,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",40,True,12,True,True,True,True,True,True,True,[],False,0.81,Approved
case_0109,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,25,True,True,True,True,True,True,True,[],False,1.0,Approved
case_0110,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0111,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0112,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.54).",10,True,12,True,False,False,True,True,False,False,['HER2+'],True,0.54,Borderline
case_0113,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0114,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,18,True,False,False,True,True,False,False,"['BRAF+', 'HER2+']",True,0.79,Approved
case_0115,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,25,True,False,False,True,True,False,False,"['ALK+', 'EGFR+']",True,0.91,Approved
case_0116,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,12,True,False,False,True,True,True,True,[],False,0.79,Approved
case_0117,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",90,True,12,True,False,False,True,True,False,False,[],False,0.81,Approved
case_0118,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0119,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,25,True,True,True,True,True,False,False,[],False,0.91,Approved
case_0120,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.65).",50,True,12,True,False,False,True,True,False,False,[],False,0.65,Borderline
case_0121,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,25,True,False,False,True,True,False,False,"['BRAF+', 'HER2+']",True,0.75,Approved
case_0122,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.66).",40,True,12,True,True,True,False,False,True,True,[],False,0.66,Borderline
case_0123,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",40,True,12,True,True,True,True,True,True,True,[],False,0.81,Approved
case_0124,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.84).",60,True,12,True,False,False,True,True,True,True,['EGFR+'],True,0.84,Approved
case_0125,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0126,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0127,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0128,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,25,True,True,True,True,True,True,True,"['HER2+', 'ALK+']",True,1.0,Approved
case_0129,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,12,True,False,False,True,True,True,True,[],False,0.95,Approved
case_0130,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0131,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.92).",80,True,18,True,False,False,True,True,True,True,['BRAF+'],True,0.92,Approved
case_0132,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,18,True,False,False,True,True,True,True,[],False,0.75,Approved
case_0133,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,18,True,True,True,True,True,False,False,[],False,0.91,Approved
case_0134,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.8).",50,True,12,True,True,True,True,True,False,False,['HER2+'],True,0.8,Approved
case_0135,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.49).,10,True,8,True,False,False,True,True,False,False,[],False,0.49,Rejected
case_0136,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.51).",40,True,8,True,False,False,False,False,False,False,['EGFR+'],True,0.51,Borderline
case_0137,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.54).",10,True,12,True,True,True,False,False,True,True,[],False,0.54,Borderline
case_0138,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0139,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,False,False,"['ALK+', 'EGFR+']",True,1.0,Approved
case_0140,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",50,True,25,True,True,True,True,True,True,True,"['ALK+', 'BRAF+']",True,0.95,Approved
case_0141,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0142,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0143,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0144,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.82).",80,True,25,True,False,False,True,True,False,False,['EGFR+'],True,0.82,Approved
case_0145,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,25,True,False,False,True,True,True,True,"['EGFR+', 'ALK+']",True,1.0,Approved
case_0146,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.61).",40,True,5,True,False,False,False,False,True,True,['EGFR+'],True,0.61,Borderline
case_0147,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0148,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0149,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0150,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.53).",20,True,8,True,False,False,True,True,False,False,[],False,0.53,Borderline
case_0151,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0152,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0153,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0154,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.65).",50,True,12,True,False,False,True,True,False,False,[],False,0.65,Borderline
case_0155,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.61).",40,True,5,True,False,False,False,False,True,True,['EGFR+'],True,0.61,Borderline
case_0156,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.8).",50,True,25,True,False,False,True,True,True,True,['ALK+'],True,0.8,Approved
case_0157,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,True,True,True,True,True,True,[],False,1.0,Approved
case_0158,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.69).",10,True,8,True,True,True,True,True,True,True,[],False,0.69,Borderline
case_0159,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,12,True,True,True,True,True,False,False,[],False,0.79,Approved
case_0160,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.65).",50,True,18,True,False,False,True,True,False,False,[],False,0.65,Borderline
case_0161,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,18,True,True,True,True,True,False,False,[],False,0.75,Approved
case_0162,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",80,True,25,True,True,True,True,True,True,True,['BRAF+'],True,1.0,Approved
case_0163,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0164,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0165,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,12,True,False,False,True,True,True,True,['EGFR+'],True,0.96,Approved
case_0166,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.7).",50,True,12,True,False,False,True,True,False,False,['BRAF+'],True,0.7,Approved
case_0167,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,25,True,True,True,True,True,True,True,[],False,0.89,Approved
case_0168,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0169,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0170,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",90,True,12,True,False,False,True,True,False,False,[],False,0.81,Approved
case_0171,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,12,True,False,False,True,True,False,False,"['HER2+', 'BRAF+']",True,0.79,Approved
case_0172,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.63).",20,True,12,True,False,False,True,True,True,True,[],False,0.63,Borderline
case_0173,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0174,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",100,True,12,True,False,False,True,True,False,False,[],False,0.85,Approved
case_0175,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,12,True,True,True,True,True,False,False,[],False,0.95,Approved
case_0176,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.8).",50,True,25,True,False,False,True,True,True,True,['EGFR+'],True,0.8,Approved
case_0177,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0178,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0179,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.86).",90,True,12,True,False,False,True,True,False,False,['HER2+'],True,0.86,Approved
case_0180,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0181,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.69).",60,True,18,True,False,False,True,True,False,False,[],False,0.69,Borderline
case_0182,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.7).",50,True,25,True,False,False,True,True,False,False,['EGFR+'],True,0.7,Approved
case_0183,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,25,True,False,False,True,True,True,True,[],False,0.79,Approved
case_0184,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,True,True,True,True,False,False,[],False,0.95,Approved
case_0185,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0186,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0187,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0188,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0189,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,25,True,False,False,True,True,True,True,['HER2+'],True,1.0,Approved
case_0190,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.99).",60,True,12,True,True,True,True,True,True,True,"['EGFR+', 'ALK+']",True,0.99,Approved
case_0191,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,18,True,True,True,True,True,False,False,[],False,0.95,Approved
case_0192,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.54).",10,True,8,True,False,False,True,True,False,False,['HER2+'],True,0.54,Borderline
case_0193,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",100,True,12,True,False,False,True,True,False,False,[],False,0.85,Approved
case_0194,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0195,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0196,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.66).",40,True,12,True,True,True,False,False,True,True,[],False,0.66,Borderline
case_0197,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,25,True,False,False,True,True,True,True,['BRAF+'],True,0.96,Approved
case_0198,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.66).",40,True,8,True,True,True,False,False,True,True,[],False,0.66,Borderline
case_0199,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.87).",80,True,18,True,False,False,True,True,False,False,"['EGFR+', 'HER2+']",True,0.87,Approved
case_0200,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.44).",10,True,12,True,True,True,False,False,False,False,[],False,0.44,Rejected
case_0201,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0202,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.49).,10,True,12,True,False,False,True,True,False,False,[],False,0.49,Rejected
case_0203,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0204,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,False,False,"['ALK+', 'HER2+']",True,1.0,Approved
case_0205,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0206,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0207,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",100,True,12,True,False,False,True,True,False,False,['BRAF+'],True,0.9,Approved
case_0208,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0209,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0210,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",100,True,25,True,False,False,True,True,False,False,[],False,0.85,Approved
case_0211,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,12,True,True,True,True,True,False,False,"['ALK+', 'BRAF+']",True,1.0,Approved
case_0212,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.63).",20,True,5,True,True,True,True,True,False,False,[],False,0.63,Borderline
case_0213,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0214,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.61).",40,True,8,True,False,False,False,False,True,True,['EGFR+'],True,0.61,Borderline
case_0215,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.56).",40,True,12,True,True,True,False,False,False,False,[],False,0.56,Borderline
case_0216,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0217,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0218,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.63).",20,True,5,True,True,True,True,True,False,False,[],False,0.63,Borderline
case_0219,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,25,True,True,True,True,True,False,False,['ALK+'],True,0.96,Approved
case_0220,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0221,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,18,True,True,True,True,True,False,False,[],False,0.95,Approved
case_0222,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0223,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0224,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",80,True,25,True,True,True,True,True,True,True,"['HER2+', 'ALK+']",True,1.0,Approved
case_0225,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,False,False,True,True,True,True,[],False,0.95,Approved
case_0226,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.44).",10,True,5,True,True,True,False,False,False,False,[],False,0.44,Rejected
case_0227,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.61).",40,True,12,True,False,False,True,True,False,False,[],False,0.61,Borderline
case_0228,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0229,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",50,True,18,True,True,True,True,True,True,True,['EGFR+'],True,0.9,Approved
case_0230,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,18,True,False,False,True,True,True,True,"['BRAF+', 'ALK+']",True,0.89,Approved
case_0231,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.65).",50,True,12,True,False,False,True,True,False,False,[],False,0.65,Borderline
case_0232,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0233,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.58).",20,True,12,True,False,False,True,True,False,False,['HER2+'],True,0.58,Borderline
case_0234,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,True,True,"['ALK+', 'HER2+']",True,1.0,Approved
case_0235,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,12,True,True,True,True,True,False,False,[],False,0.91,Approved
case_0236,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0237,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",90,True,12,True,False,False,True,True,False,False,[],False,0.81,Approved
case_0238,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0239,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.58).",20,True,8,True,False,False,True,True,False,False,['EGFR+'],True,0.58,Borderline
case_0240,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",80,True,12,True,True,True,True,True,True,True,['EGFR+'],True,1.0,Approved
case_0241,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.74).",60,True,12,True,False,False,True,True,False,False,['HER2+'],True,0.74,Approved
case_0242,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0243,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.56).",40,True,12,True,False,False,False,False,True,True,[],False,0.56,Borderline
case_0244,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",50,True,25,True,True,True,True,True,True,True,['EGFR+'],True,0.9,Approved
case_0245,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0246,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0247,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.92).",80,True,12,True,True,True,True,True,False,False,['ALK+'],True,0.92,Approved
case_0248,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0249,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0250,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",50,True,18,True,True,True,True,True,True,True,['BRAF+'],True,0.9,Approved
case_0251,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,25,True,False,False,True,True,True,True,"['BRAF+', 'HER2+']",True,0.97,Approved
case_0252,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0253,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0254,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0255,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.69).",60,True,18,True,False,False,True,True,False,False,[],False,0.69,Borderline
case_0256,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0257,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0258,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.68).",20,True,12,True,False,False,True,True,True,True,['HER2+'],True,0.68,Borderline
case_0259,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0260,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0261,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,18,True,False,False,True,True,False,False,"['EGFR+', 'HER2+']",True,0.79,Approved
case_0262,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,25,True,False,False,True,True,True,True,[],False,0.75,Approved
case_0263,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.7).",50,True,12,True,False,False,True,True,False,False,['HER2+'],True,0.7,Approved
case_0264,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,True,True,True,True,True,True,[],False,1.0,Approved
case_0265,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.69).",10,True,8,True,True,True,True,True,True,True,[],False,0.69,Borderline
case_0266,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.61).",40,True,5,True,True,True,False,False,False,False,['EGFR+'],True,0.61,Borderline
case_0267,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.8).",50,True,18,True,False,False,True,True,True,True,['ALK+'],True,0.8,Approved
case_0268,The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.46).,40,True,8,True,False,False,False,False,False,False,[],False,0.46,Rejected
case_0269,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0270,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,25,True,False,False,True,True,True,True,[],False,0.91,Approved
case_0271,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",100,True,25,True,False,False,True,True,False,False,[],False,0.85,Approved
case_0272,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0273,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.58).",20,True,5,True,True,True,False,False,True,True,[],False,0.58,Borderline
case_0274,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0275,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,25,True,True,True,True,True,False,False,[],False,0.91,Approved
case_0276,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,18,True,True,True,True,True,False,False,[],False,0.75,Approved
case_0277,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.51).",40,True,8,True,False,False,False,False,False,False,['HER2+'],True,0.51,Borderline
case_0278,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,False,False,"['ALK+', 'EGFR+']",True,1.0,Approved
case_0279,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0280,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0281,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0282,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.8).",50,True,12,True,True,True,True,True,False,False,['HER2+'],True,0.8,Approved
case_0283,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.59).",10,True,12,True,True,True,False,False,True,True,['EGFR+'],True,0.59,Borderline
case_0284,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0285,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0286,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.48).",20,True,12,True,True,True,False,False,False,False,[],False,0.48,Rejected
case_0287,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",100,True,18,True,False,False,True,True,False,False,[],False,0.85,Approved
case_0288,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",50,True,18,True,True,True,True,True,True,True,[],False,0.85,Approved
case_0289,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.63).",20,True,8,True,False,False,True,True,True,True,[],False,0.63,Borderline
case_0290,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,12,True,False,False,True,True,True,True,[],False,0.71,Approved
case_0291,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,18,True,False,False,True,True,False,False,"['HER2+', 'EGFR+']",True,0.91,Approved
case_0292,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0293,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0294,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.44).",10,True,5,True,True,True,False,False,False,False,[],False,0.44,Rejected
case_0295,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0296,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0297,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0298,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0299,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.68).",20,True,12,True,False,False,True,True,True,True,['HER2+'],True,0.68,Borderline
case_0300,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0301,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,True,True,True,True,True,True,"['HER2+', 'EGFR+']",True,1.0,Approved
case_0302,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0303,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,8,True,True,True,False,False,True,True,['EGFR+'],True,0.71,Approved
case_0304,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.92).",80,True,18,True,False,False,True,True,True,True,['HER2+'],True,0.92,Approved
case_0305,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0306,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0307,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.49).,10,True,8,True,False,False,True,True,False,False,[],False,0.49,Rejected
case_0308,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.87).",80,True,12,True,True,True,True,True,False,False,[],False,0.87,Approved
case_0309,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0310,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.66).",40,True,5,True,True,True,False,False,True,True,[],False,0.66,Borderline
case_0311,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0312,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,18,True,True,True,True,True,False,False,"['HER2+', 'EGFR+']",True,0.89,Approved
case_0313,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,18,True,False,False,True,True,False,False,"['EGFR+', 'ALK+']",True,0.79,Approved
case_0314,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0315,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0316,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0317,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.58).",20,True,12,True,False,False,True,True,False,False,['EGFR+'],True,0.58,Borderline
case_0318,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0319,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0320,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.92).",80,True,18,True,False,False,True,True,True,True,['BRAF+'],True,0.92,Approved
case_0321,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0322,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0323,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.59).",10,True,8,True,True,True,False,False,True,True,['EGFR+'],True,0.59,Borderline
case_0324,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",50,True,18,True,True,True,True,True,True,True,['ALK+'],True,0.9,Approved
case_0325,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0326,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,False,False,True,True,True,True,[],False,0.95,Approved
case_0327,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,18,True,False,False,True,True,False,False,"['BRAF+', 'EGFR+']",True,0.75,Approved
case_0328,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0329,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,12,True,False,False,True,True,True,True,['ALK+'],True,0.96,Approved
case_0330,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0331,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0332,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0333,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",50,True,25,True,True,True,True,True,True,True,"['HER2+', 'EGFR+']",True,0.95,Approved
case_0334,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",50,True,12,True,True,True,True,True,True,True,"['HER2+', 'EGFR+']",True,0.95,Approved
case_0335,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.69).",10,True,5,True,True,True,True,True,True,True,[],False,0.69,Borderline
case_0336,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0337,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0338,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,True,True,True,True,True,True,['BRAF+'],True,1.0,Approved
case_0339,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0340,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.8).",50,True,18,True,False,False,True,True,True,True,['BRAF+'],True,0.8,Approved
case_0341,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0342,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.87).",80,True,25,True,False,False,True,True,True,True,[],False,0.87,Approved
case_0343,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,True,True,True,True,False,False,[],False,0.95,Approved
case_0344,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.76).",40,True,12,True,False,False,True,True,True,True,['HER2+'],True,0.76,Approved
case_0345,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,False,False,True,True,True,True,[],False,0.95,Approved
case_0346,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,25,True,False,False,True,True,True,True,"['BRAF+', 'EGFR+']",True,1.0,Approved
case_0347,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.64).",10,True,8,True,False,False,True,True,True,True,['HER2+'],True,0.64,Borderline
case_0348,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,12,True,False,False,True,True,False,False,"['HER2+', 'ALK+']",True,0.75,Approved
case_0349,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,True,True,True,True,False,False,[],False,0.95,Approved
case_0350,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",50,True,12,True,True,True,True,True,True,True,['EGFR+'],True,0.9,Approved
case_0351,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0352,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,25,True,False,False,True,True,True,True,['EGFR+'],True,1.0,Approved
case_0353,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.53).",20,True,5,True,True,True,False,False,False,False,['EGFR+'],True,0.53,Borderline
case_0354,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0355,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.68).",20,True,5,True,True,True,True,True,False,False,['EGFR+'],True,0.68,Borderline
case_0356,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0357,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0358,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.59).",10,True,8,True,False,False,True,True,True,True,[],False,0.59,Borderline
case_0359,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,18,True,False,False,True,True,True,True,[],False,0.91,Approved
case_0360,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.58).",20,True,5,True,False,False,True,True,False,False,['EGFR+'],True,0.58,Borderline
case_0361,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,25,True,False,False,True,True,True,True,"['ALK+', 'HER2+']",True,1.0,Approved
case_0362,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0363,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0364,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.9).",100,True,18,True,False,False,True,True,False,False,['EGFR+'],True,0.9,Approved
case_0365,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,12,True,True,True,True,True,False,False,"['BRAF+', 'HER2+']",True,0.97,Approved
case_0366,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",50,True,12,True,True,True,True,True,False,False,"['HER2+', 'ALK+']",True,0.85,Approved
case_0367,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.63).",20,True,8,True,True,True,False,False,True,True,['EGFR+'],True,0.63,Borderline
case_0368,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0369,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.94).",60,True,25,True,True,True,True,True,True,True,['ALK+'],True,0.94,Approved
case_0370,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,25,True,True,True,True,True,False,False,"['HER2+', 'EGFR+']",True,1.0,Approved
case_0371,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0372,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0373,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0374,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,25,True,True,True,True,True,False,False,[],False,0.75,Approved
case_0375,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.73).",20,True,5,True,True,True,True,True,True,True,[],False,0.73,Approved
case_0376,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0377,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,12,True,True,True,True,True,True,True,['BRAF+'],True,1.0,Approved
case_0378,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.59).",10,True,8,True,True,True,True,True,False,False,[],False,0.59,Borderline
case_0379,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0380,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,True,True,[],False,1.0,Approved
case_0381,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0382,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.64).",10,True,5,True,False,False,True,True,True,True,['EGFR+'],True,0.64,Borderline
case_0383,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0384,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,18,True,True,True,True,True,True,True,"['ALK+', 'BRAF+']",True,1.0,Approved
case_0385,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,12,True,True,True,True,True,True,True,[],False,0.89,Approved
case_0386,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0387,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.74).",60,True,18,True,False,False,True,True,False,False,['HER2+'],True,0.74,Approved
case_0388,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.54).",10,True,5,True,True,True,False,False,True,True,[],False,0.54,Borderline
case_0389,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0390,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,18,True,True,True,True,True,False,False,['EGFR+'],True,0.96,Approved
case_0391,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.66).",40,True,12,True,False,False,True,True,False,False,['HER2+'],True,0.66,Borderline
case_0392,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,5,True,True,True,False,False,True,True,['EGFR+'],True,0.71,Approved
case_0393,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.56).",40,True,8,True,True,True,False,False,False,False,[],False,0.56,Borderline
case_0394,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0395,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.87).",80,True,18,True,True,True,True,True,False,False,[],False,0.87,Approved
case_0396,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.63).",20,True,5,True,True,True,True,True,False,False,[],False,0.63,Borderline
case_0397,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,25,True,True,True,True,True,False,False,[],False,0.79,Approved
case_0398,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.71).",40,True,12,True,False,False,True,True,True,True,[],False,0.71,Approved
case_0399,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.74).",10,True,8,True,True,True,True,True,True,True,['HER2+'],True,0.74,Approved
case_0400,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",50,True,18,True,True,True,True,True,True,True,[],False,0.85,Approved
case_0401,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.54).",10,True,8,True,True,True,False,False,True,True,[],False,0.54,Borderline
case_0402,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0403,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,25,True,True,True,True,True,False,False,"['BRAF+', 'HER2+']",True,0.97,Approved
case_0404,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,False,False,True,True,True,True,['ALK+'],True,1.0,Approved
case_0405,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,12,True,True,True,True,True,False,False,['BRAF+'],True,0.96,Approved
case_0406,The tumor shows 20% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.38).,20,True,12,True,False,False,False,False,False,False,[],False,0.38,Rejected
case_0407,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",80,True,18,True,True,True,True,True,True,True,"['HER2+', 'EGFR+']",True,1.0,Approved
case_0408,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.86).",40,True,12,True,True,True,True,True,True,True,['EGFR+'],True,0.86,Approved
case_0409,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,25,True,False,False,True,True,False,False,"['BRAF+', 'HER2+']",True,0.91,Approved
case_0410,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.53).",20,True,5,True,True,True,False,False,False,False,['HER2+'],True,0.53,Borderline
case_0411,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0412,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.64).",10,True,8,True,False,False,True,True,True,True,['EGFR+'],True,0.64,Borderline
case_0413,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0414,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,12,True,True,True,True,True,True,True,[],False,0.97,Approved
case_0415,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0416,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0417,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.68).",20,True,8,True,False,False,True,True,True,True,['EGFR+'],True,0.68,Borderline
case_0418,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0419,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0420,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,False,False,True,True,True,True,['BRAF+'],True,1.0,Approved
case_0421,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.95).",100,True,25,True,False,False,True,True,True,True,[],False,0.95,Approved
case_0422,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0423,"The tumor shows 20% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.53).",20,True,5,True,True,True,False,False,False,False,['EGFR+'],True,0.53,Borderline
case_0424,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.66).",40,True,8,True,False,False,True,True,False,False,['HER2+'],True,0.66,Borderline
case_0425,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0426,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0427,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,12,True,False,False,True,True,False,False,"['ALK+', 'BRAF+']",True,0.79,Approved
case_0428,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,False,False,True,True,True,True,"['ALK+', 'EGFR+']",True,1.0,Approved
case_0429,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.69).",10,True,5,True,True,True,True,True,True,True,[],False,0.69,Borderline
case_0430,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.89).",60,True,25,True,True,True,True,True,True,True,[],False,0.89,Approved
case_0431,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.56).",40,True,8,True,True,True,False,False,False,False,[],False,0.56,Borderline
case_0432,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0433,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,12,True,True,True,True,True,True,True,[],False,0.97,Approved
case_0434,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",90,True,12,True,False,False,True,True,False,False,[],False,0.81,Approved
case_0435,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.81).",90,True,25,True,False,False,True,True,False,False,[],False,0.81,Approved
case_0436,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0437,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0438,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0439,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.65).",50,True,18,True,False,False,True,True,False,False,[],False,0.65,Borderline
case_0440,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0441,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0442,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",50,True,18,True,True,True,True,True,True,True,[],False,0.85,Approved
case_0443,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0444,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,True,True,[],False,1.0,Approved
case_0445,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0446,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.85).",50,True,12,True,False,False,True,True,True,True,"['BRAF+', 'ALK+']",True,0.85,Approved
case_0447,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0448,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0449,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,12,True,True,True,True,True,False,False,"['HER2+', 'BRAF+']",True,1.0,Approved
case_0450,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0451,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.74).",60,True,12,True,False,False,True,True,False,False,['EGFR+'],True,0.74,Approved
case_0452,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.79).",60,True,25,True,False,False,True,True,True,True,[],False,0.79,Approved
case_0453,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,18,True,True,True,True,True,False,False,['HER2+'],True,1.0,Approved
case_0454,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.64).",10,True,8,True,True,True,True,True,False,False,['HER2+'],True,0.64,Borderline
case_0455,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0456,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.74).",60,True,18,True,False,False,True,True,False,False,['BRAF+'],True,0.74,Approved
case_0457,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0458,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.86).",90,True,12,True,False,False,True,True,False,False,['BRAF+'],True,0.86,Approved
case_0459,"The tumor shows 60% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. A BRAF mutation is present, which may guide therapy options. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.99).",60,True,18,True,True,True,True,True,True,True,"['BRAF+', 'EGFR+']",True,0.99,Approved
case_0460,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0461,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,25,True,False,False,True,True,False,False,"['ALK+', 'EGFR+']",True,0.75,Approved
case_0462,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,18,True,True,True,True,True,False,False,"['ALK+', 'HER2+']",True,1.0,Approved
case_0463,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0464,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,12,True,True,True,True,True,False,False,[],False,0.75,Approved
case_0465,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0466,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,25,True,False,False,True,True,True,True,['EGFR+'],True,0.96,Approved
case_0467,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0468,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0469,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0470,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.97).",80,True,18,True,True,True,True,True,False,False,"['ALK+', 'BRAF+']",True,0.97,Approved
case_0471,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0472,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. There has been a failure of prior therapy. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.59).",10,True,8,True,True,True,False,False,True,True,['EGFR+'],True,0.59,Borderline
case_0473,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.64).",10,True,5,True,True,True,True,True,False,False,['EGFR+'],True,0.64,Borderline
case_0474,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0475,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",90,True,25,True,True,True,True,True,True,True,[],False,1.0,Approved
case_0476,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.8).",50,True,12,True,False,False,True,True,True,True,['ALK+'],True,0.8,Approved
case_0477,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An ALK mutation is detected, opening possibilities for ALK inhibitors. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,25,True,True,True,True,True,False,False,['ALK+'],True,1.0,Approved
case_0478,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.75).",50,True,12,True,False,False,True,True,True,True,[],False,0.75,Approved
case_0479,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.49).",10,True,5,True,False,False,False,False,True,True,['HER2+'],True,0.49,Rejected
case_0480,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.59).",10,True,5,True,True,True,True,True,False,False,[],False,0.59,Borderline
case_0481,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0482,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.91).",90,True,12,True,True,True,True,True,False,False,[],False,0.91,Approved
case_0483,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0484,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0485,"The tumor shows 100% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. A BRAF mutation is present, which may guide therapy options. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 1.0).",100,True,12,True,False,False,True,True,True,True,"['HER2+', 'BRAF+']",True,1.0,Approved
case_0486,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0487,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0488,"The tumor shows 40% expression of PD-L1. The tumor mutational burden is 8 mut/Mb. There has been a failure of prior therapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.61).",40,True,8,True,False,False,False,False,True,True,['HER2+'],True,0.61,Borderline
case_0489,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,2,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0490,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,2,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0491,"The tumor shows 80% expression of PD-L1. The tumor mutational burden is 18 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.77).",80,True,18,True,False,False,True,True,False,False,[],False,0.77,Approved
case_0492,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0493,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. There has been a failure of prior therapy. The biomarker profile shows intermediate features, requiring further human expert review (risk score: 0.59).",10,True,5,True,False,False,True,True,True,True,[],False,0.59,Borderline
case_0494,The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.34).,10,True,5,True,False,False,False,False,False,False,[],False,0.34,Rejected
case_0495,"The tumor shows 50% expression of PD-L1. The tumor mutational burden is 12 mut/Mb. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.7).",50,True,12,True,False,False,True,True,False,False,['EGFR+'],True,0.7,Approved
case_0496,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,5,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0497,The tumor shows 0% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.3).,0,True,5,True,False,False,False,False,False,False,[],False,0.3,Rejected
case_0498,"The tumor shows 90% expression of PD-L1. The tumor mutational burden is 25 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. The disease is showing progressive behavior despite ongoing treatment. An EGFR mutation is present, which may influence targeted therapy decisions. Overall, the biomarker profile indicates a high likelihood of benefit from advanced therapy (risk score: 0.96).",90,True,25,True,True,True,True,True,False,False,['EGFR+'],True,0.96,Approved
case_0499,The tumor shows 5% expression of PD-L1. The tumor mutational burden is 2 mut/Mb. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.32).,5,True,2,True,False,False,False,False,False,False,[],False,0.32,Rejected
case_0500,"The tumor shows 10% expression of PD-L1. The tumor mutational burden is 5 mut/Mb. Microsatellite instability-high (MSI-H) is detected, indicating potential benefit from immunotherapy. HER2 overexpression is observed, potentially indicating HER2-targeted therapies. Biomarker indicators suggest a low probability of success with advanced therapy (risk score: 0.49).",10,True,5,True,True,True,False,False,False,False,['HER2+'],True,0.49,Rejected
